U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H21NO7
Molecular Weight 267.2762
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VOGLIBOSE

SMILES

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=FZNCGRZWXLXZSZ-CIQUZCHMSA-N
InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

HIDE SMILES / InChI
Molecular Formula C10H21NO7
Molecular Weight 267.2762
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Voglibose is an alpha glucosidase inhibitor, which was initially marketed in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus. Later on the drug was approved for the prevention of type 2 diabetes. The drug is available in Asia under the name Basen.

Originator

Takeda Pharmaceutical
69

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
alpha-Glucosidase
1
Inhibitor
8,297

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diabetes mellitus
91
 Primary
Approved
8,429
BASEN
Type 2 diabetes mellitus
259
 Preventing
Approved
8,429
BASEN

PubMed

Patents

JP2000103731A
7
JP2000344660A
1
JP2000504736A
1
JP2000505784A
1
JP2000507197A
1
JP2000515113A
1
JP2001002567A
1
JP2001509795A
2
JP2001515084A
1
JP2001523704A
2
JP2002500643A
10
JP2002520418A
1
JP2002537393A
1
JP2002542232A
1
JP2002542344A
1
JP2003500078A
1
JP2003500474A
1
JP2003500475A
1
JP2003505358A
1
JP2003506426A
1
JP2003509401A
1
JP2003510350A
1
JP2003511451A
1
JP2003517303A
1
JP2003517466A
1
JP2003522758A
4
JP2004315496A
25
JP2004502792A
1
JP2004525900A
3
JP2004527465A
1
JP2004536830A
1
JP2005502735A
1
JP2005511566A
1
JP2005511570A
1
JP2005511694A
1
JP2005512806A
1
JP2005516018A
1
JP2005522496A
1
JP2005522510A
1
JP2005522511A
1
JP2005526795A
3
JP2005535584A
1
JP2005535649A
1
JP2005538073A
1
JP2005538968A
1
JP2006008548A
1
JP2006016388A
1
JP2006131564A
1
JP2006501063A
1
JP2006502119A
1
JP2006503013A
1

Sample Use Guides

In Vivo Use Guide
Tablets are orally administered in a single dose of 0.2 mg as voglibose, three times a day, just before each meal.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
S77P977AG8
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966